Profile data is unavailable for this security.
About the company
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
- Revenue in USD (TTM)2.95bn
- Net income in USD122.19m
- Incorporated2019
- Employees6.13k
- LocationBiontech SEAn der Goldgrube 12MAINZ 55131GermanyDEU
- Phone+49 49 613190840
- Fax+49 61 319084390
- Websitehttps://www.biontech.com/
Mergers & acquisitions
Acquired company | 22UA:GER since announced | Transaction value |
---|---|---|
AexeRNA Therapeutics LLC | 3.05% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BIO-TECHNE Corp | 1.15bn | 202.97m | 12.67bn | 3.05k | 63.94 | 6.29 | 40.41 | 10.98 | 1.26 | 1.26 | 7.16 | 12.79 | 0.4339 | 2.20 | 5.20 | 378,452.80 | 7.63 | 9.57 | 8.07 | 10.20 | 66.80 | 67.35 | 17.59 | 21.91 | 2.88 | 14.00 | 0.1619 | 24.19 | 2.81 | 12.07 | 4.88 | 25.13 | 12.81 | 0.00 |
Incyte Corp | 3.77bn | 745.44m | 12.90bn | 2.52k | 17.44 | 2.39 | 15.53 | 3.42 | 3.29 | 3.29 | 16.64 | 24.02 | 0.5827 | 4.52 | 5.50 | 1,492,815.00 | 11.53 | 9.07 | 14.16 | 11.02 | 93.73 | 94.97 | 19.78 | 13.68 | 3.43 | -- | 0.006 | 0.00 | 8.87 | 14.45 | 75.42 | 40.41 | -15.06 | -- |
Natera Inc | 1.21bn | -365.46m | 13.20bn | 3.28k | -- | 16.55 | -- | 10.92 | -3.13 | -3.13 | 10.31 | 6.50 | 0.8673 | 14.36 | 4.51 | 368,237.70 | -26.23 | -36.17 | -33.37 | -46.60 | 50.28 | 45.88 | -30.24 | -56.15 | 3.98 | -- | 0.3141 | -- | 31.99 | 33.26 | 20.63 | -- | 58.81 | -- |
Neurocrine Biosciences, Inc. | 1.98bn | 369.70m | 14.14bn | 1.45k | 38.61 | 5.92 | 36.05 | 7.13 | 3.64 | 3.64 | 19.47 | 23.72 | 0.6797 | 1.10 | 4.71 | 1,415,714.00 | 12.68 | 9.77 | 15.58 | 12.19 | 98.05 | 98.51 | 18.65 | 14.79 | 2.47 | -- | 0.049 | -- | 26.76 | 33.13 | 61.62 | 63.90 | 2.67 | -- |
Biomarin Pharmaceutical Inc | 2.47bn | 205.46m | 14.41bn | 3.40k | 71.84 | 2.84 | 46.37 | 5.83 | 1.06 | 1.06 | 12.77 | 26.74 | 0.3715 | 0.4993 | 4.00 | 726,740.40 | 3.09 | 0.7773 | 3.54 | 0.8825 | 79.22 | 76.30 | 8.31 | 2.24 | 1.70 | -- | 0.1766 | 0.00 | 15.42 | 10.16 | 18.43 | -- | -5.74 | -- |
Alnylam Pharmaceuticals, Inc. | 2.00bn | -332.08m | 18.90bn | 2.10k | -- | -- | -- | 9.43 | -2.71 | -2.71 | 15.78 | -1.73 | 0.5552 | 2.85 | 11.67 | 953,969.10 | -9.20 | -26.56 | -11.86 | -32.77 | 83.95 | 83.66 | -16.58 | -94.26 | 3.07 | -1.37 | 1.27 | -- | 76.23 | 89.45 | 61.08 | -- | -13.29 | -- |
BioNTech SE - ADR | 2.95bn | 122.19m | 23.53bn | 6.13k | 192.49 | 1.09 | 71.76 | 7.97 | 0.5143 | 0.5143 | 12.28 | 90.83 | 0.1231 | 1.46 | 0.6733 | 481,253.10 | 0.5098 | 37.91 | 0.5488 | 44.76 | 79.38 | 83.82 | 4.14 | 50.36 | 11.16 | -- | 0.0117 | 4.73 | -77.94 | 97.35 | -90.14 | -- | 60.06 | -- |
ICON PLC | 8.23bn | 683.12m | 26.46bn | 41.10k | 38.83 | 2.81 | 20.78 | 3.21 | 8.24 | 8.24 | 99.33 | 114.08 | 0.4795 | -- | 2.92 | 200,291.60 | 3.98 | 3.93 | 4.80 | 4.80 | 29.67 | 28.91 | 8.30 | 7.37 | -- | 3.48 | 0.2706 | -- | 4.89 | 25.62 | 21.18 | 13.67 | 23.79 | -- |
Biogen Inc | 9.66bn | 1.17bn | 31.75bn | 7.57k | 27.25 | 2.09 | 18.70 | 3.29 | 8.00 | 8.00 | 66.40 | 104.48 | 0.3777 | 1.27 | 4.80 | 1,276,499.00 | 4.56 | 12.53 | 5.20 | 14.83 | 75.03 | 81.84 | 12.08 | 26.93 | 1.32 | 3.78 | 0.3007 | 0.00 | -3.32 | -6.07 | -61.89 | -23.58 | -18.87 | -- |
DuPont de Nemours Inc | 11.98bn | 404.00m | 33.00bn | 24.00k | 90.35 | 1.40 | 20.57 | 2.75 | 0.8736 | 0.8126 | 27.12 | 56.41 | 0.3036 | 3.37 | 4.99 | 499,208.30 | 1.12 | 0.3709 | 1.24 | 0.468 | 35.15 | 35.69 | 3.70 | 1.97 | 1.61 | 6.24 | 0.2446 | 414.03 | -7.29 | -11.79 | -51.19 | 11.24 | -30.66 | -20.59 |
Holder | Shares | % Held |
---|---|---|
Baillie Gifford & Co.as of 31 Mar 2024 | 8.36m | 3.52% |
PRIMECAP Management Co.as of 31 Mar 2024 | 4.81m | 2.02% |
Harding Loevner LPas of 31 Mar 2024 | 3.82m | 1.61% |
Flossbach von Storch AGas of 31 Mar 2024 | 3.47m | 1.46% |
Temasek Holdings Pte Ltd. (Investment Management)as of 31 Mar 2024 | 3.43m | 1.44% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 1.61m | 0.68% |
Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 943.12k | 0.40% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 828.93k | 0.35% |
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 814.00k | 0.34% |
Quinn Opportunity Partners LLCas of 31 Mar 2024 | 713.38k | 0.30% |